🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - Mike Thompson, MD, PhD, FASCO - Update: 12/4/24 - cc Surviving Myeloma - Ben Derman Binod Dhakal C. Ola Landgren, M.D. Luciano J Costa Samer Al Hadidi, MD,MS,FACP Joseph Mikhael Manni Mohyuddin Meera Mohan @MyelomaTeacher - Cindy Chmielewski Rahul Banerjee, MD, FACP Raj Chakraborty Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰

Thank you very much Multiple Myeloma RF for supporting our talented physician-scientist Dr. Marcella Kaddoura and her work on BCL2 inhibitors in myeloma at Sylvester Comprehensive Cancer Center, University of Miami! #msmm #ASH24 Marcella Kaddoura, MD International Myeloma Foundation HealthTree Foundation ASH The Leukemia & Lymphoma Society Stephen D. Nimer, MD University of Miami

Just arrived in San Diego ready to attend the annual #ASH24 conference. Lots of new data & ideas will be shared here during the meeting. Looking forward to networking with colleagues & friends from all over the world #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩

Dr. Marcela Kaddoura presenting on genomic determinants of clinical outcomes in t(11;14). #ASH24RF #MMSM CCND1 simple aligns with CD2 (CD20). Expression of early B cell markers correspond to response. Francesco Maura #ASH24RF #mmsm

BCMA loss after was rare (5%) but highly predictive of outcome after BCMA CAR T therapy #mmsm #ASH24

20 years of collaboration and friendship. Vincent Vincent Rajkumar & I have done numerous studies together on myeloma precursor disease. During ASH we always meet up 1:1 and chat for 1-2 hrs. Friendship goes beyond work! International Myeloma Foundation Multiple Myeloma RF HealthTree Foundation #mmsm #ash24 Sylvester Comprehensive Cancer Center

MRD - an Early ⁦FDA Oncology⁩ Endpoint for Accelerated Drug Approval in Myeloma: Roadmap on How to Cut Timelines by a Decade #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ ⁦The Leukemia & Lymphoma Society⁩ ⁦Sylvester Comprehensive Cancer Center⁩ ⁦AACR⁩ #ash24 pubmed.ncbi.nlm.nih.gov/39630969/

Efficacy & Safety of Daratumumab in Intermediate/High-risk Smoldering Myeloma: Final Analysis of CENTAURUS Study. With 7 yrs median followup it highlights the tolerability of Daratumumab & supports ongoing trials #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ pubmed.ncbi.nlm.nih.gov/39652826/

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma #mmsm International Myeloma Foundation Multiple Myeloma RF HealthTree Foundation The Leukemia & Lymphoma Society sanofi.com/en/media-room/…

Excited to be part of the Miami Myeloma MRD Meeting 2025! Honored to discuss the ADVANCE clinical trial on April 11. Huge thanks to my mentor C. Ola Landgren, M.D. for his guidance and support! #MultipleMyeloma #MMsm Sylvester Comprehensive Cancer Center Miami Hematology Oncology Program Director HealthTree Foundation Multiple Myeloma RF International Myeloma Foundation

MMRF’s Chief Medical Officer Hearn Jay Cho MD, PhD, joined a powerful panel on the future of MRD in myeloma at #MRD2025 in Miami — featuring voices from patients, physicians & scientists. #MyelomaMRD2025 #MultipleMyeloma #CancerResearch #HealthEquity C. Ola Landgren, M.D. Sylvester Comprehensive Cancer Center

ICYMI: In newly diagnosed multiple myeloma (NDMM), the addition of daratumumab (D) to the KRd regimen significantly improved minimal residual disease (MRD) negativity. In the ADVANCE clinical trial (NCT04268498), 306 patients received either DKRd or KRd for 8 cycles. Results

NEWS from #ASCO 2025: New Standard of Care Emerges in Newly Diagnosed Multiple Myeloma - DaraKRd - The ASCO Post #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ ⁦Sylvester Comprehensive Cancer Center⁩⁩ ⁦ASH⁩ ⁦The Leukemia & Lymphoma Society⁩ ascopost.com/news/june-2025…

FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed/refractory multiple myeloma in patients who have received at least 4 lines of prior therapy #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ pharmacytimes.com/view/fda-appro…

NEW STUDY ONLINE Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies #mmsm ⁦International Myeloma Foundation⁩ ⁦Multiple Myeloma RF⁩ ⁦HealthTree Foundation⁩ ⁦ASH⁩ ⁦Sylvester Comprehensive Cancer Center⁩ ⁦University of Miami⁩ ashpublications.org/bloodadvances/…